Presentation is loading. Please wait.

Presentation is loading. Please wait.

TAVI „Catch me if you can!“

Published byHelena Miller Modified over 6 years ago

Similar presentations

Presentation on theme: "TAVI „Catch me if you can!“"— Presentation transcript:

1 TAVI „Catch me if you can!“

2 Eberhard Grube, MD Honoraria: Boston Scientific Corporation
Biosensors International Consulting Fees: Medtronic CoreValve Cordis Corporation Johnson & Johnson Abbott Vascular

3 Eberhard Grube, MD Ownership Interest (Stocks, Stock Options, or other Ownership Interest): Medtronic Core Valve Biosensors International My presentation will include off-label discussions: Off-label use of Stents and Valve Prosthesis

4 Patient characteristics
Patient Demographics Past Surgical History Age: 79 years Gender: male Pacemaker implantation (2006) PCI LMS/RCX (2006) PCI D1 (Oct 2011) Past Medical History Non-Hodgkin lymphoma (2001) Ischemic stroke (2005) Coronary artery disease Chronic renal failure (eGFR 35 mL/min) Atrial fibrillation COPD Pulmonary hypertension (sPAP 60 mmHg) Upper GI-bleeding (Oct 2011) Clinical Presentation Dyspnea NYHA IV Acute cardiac decompensation with pleural effusions

5 Screening Imaging Studies Procedural Strategy Clinical Indication
Heart catheterization: 2-vessel-CAD with patent stents in LMS, RCX and D1 CT scan: Aortic annulus 27.9 x 23.5 mm2, perimeter 81 mm Sufficient diameter of aortoiliac vessels for transfemoral access Echo: Severe aortic stenosis, AVA 0.9 cm2, annulus 28 mm, AR 2, MR 1 Procedural Strategy Transfemoral TAVI (31mm prosthesis) with cerebral protection device Clinical Indication Severe aortic stenosis with comorbidities High surgical risk (STS score 9.3%, log. EuroSCORE 37.4%)

6 Aortic annulus Max. diameter: 27.9mm Min. diameter: 23.5mm
Perimeter: 81 mm

7

8

9

10

11

12

13 Aortic regurgitation Index = [(RRdia – LVEDP) / RRsys] x 100
RRsys 110 mmHg RRdia 37 mmHg LVEDP 7 mmHg Aortic regurgitation Index = [(RRdia – LVEDP) / RRsys] x 100 = [(35 - 7) / 110] x 100 = 25.5

14 11.74mm 10.83mm

15

16 Clinical course post-TAVI
Patient stable without need for catecholamines after the procedure Development of acute kidney injury on day 2 Acute cardiorenal syndrome with pleural effusions and dyspnea NYHA IV

17

18 Aortic regurgitation Index = [(RRdia – LVEDP) / RRsys] x 100
RRsys 120 mmHg RRdia 40 mmHg LVEDP 20 mmHg Aortic regurgitation Index = [(RRdia – LVEDP) / RRsys] x 100 = [(40 – 20) / 120] x 100 = 16.7

19

20 13.20mm +1.5mm 12.33mm +1.5mm

21

22

23

24 4.18mm -9.0mm 3.16mm -9.2mm

25 Aortic regurgitation Index = [(RRdia – LVEDP) / RRsys] x 100
RRsys 150 mmHg RRdia 60 mmHg LVEDP 15 mmHg Aortic regurgitation Index = [(RRdia – LVEDP) / RRsys] x 100 = [( ) / 150] x 100 = 30.0

26 Moderate/Severe periprosthetic AR
Blue: Medtronic CoreValve Green: Edwards-SAPIEN

27 Periprosthetic Aortic Regurgitation
Sinning, Grube, et al., JACC in press

28 Impact of peri-AR on 1-year survival
Sinning, Grube, et al., JACC in press

29 Hemodynamics of mild peri AR
Sinning, Grube, et al., JACC in press

30 Moderate/Severe peri AR
Sinning, Grube, et al., JACC in press

31 AR index and severity of periAR
Sinning, Grube, et al., JACC in press

32 Impact of AR Index on 1-year survival
Sinning, Grube, et al., JACC in press

33 Thank you very much

Download ppt "TAVI „Catch me if you can!“"

Similar presentations

Ghanem et al., J Am Coll Cardiol 2010;55:1427–32..

Ghanem et al., J Am Coll Cardiol 2010;55:1427–32..
INTERNATIONAL. CAUTION: For distribution only in markets where CoreValve ® has been approved. The CoreValve ® System is not currently approved in the USA,

INTERNATIONAL. CAUTION: For distribution only in markets where CoreValve ® has been approved. The CoreValve ® System is not currently approved in the USA,
STS 2015 John V. Conte, MD Professor of Surgery Johns Hopkins University School of Medicine On Behalf of the CoreValve US Investigators Transcatheter Aortic.

STS 2015 John V. Conte, MD Professor of Surgery Johns Hopkins University School of Medicine On Behalf of the CoreValve US Investigators Transcatheter Aortic.
Trileaflet Aortic Valve. Management strategy for patients with chronic severe aortic regurgitation. Preoperative coronary angiography should be performed.

Trileaflet Aortic Valve. Management strategy for patients with chronic severe aortic regurgitation. Preoperative coronary angiography should be performed.
ACC 2015 Michael J Reardon, MD, FACC On Behalf of the CoreValve US Investigators A Randomized Comparison of Self-expanding Transcatheter and Surgical Aortic.

ACC 2015 Michael J Reardon, MD, FACC On Behalf of the CoreValve US Investigators A Randomized Comparison of Self-expanding Transcatheter and Surgical Aortic.
Long-Term Outcomes Using a Self- Expanding Bioprosthesis in Patients With Severe Aortic Stenosis Deemed Extreme Risk for Surgery: Two-Year Results From.

Long-Term Outcomes Using a Self- Expanding Bioprosthesis in Patients With Severe Aortic Stenosis Deemed Extreme Risk for Surgery: Two-Year Results From.
University Heart Center Hamburg

University Heart Center Hamburg
Impact of Concomitant Tricuspid Annuloplasty on Tricuspid Regurgitation Right Ventricular Function and Pulmonary Artery Hypertension After Degenerative.

Impact of Concomitant Tricuspid Annuloplasty on Tricuspid Regurgitation Right Ventricular Function and Pulmonary Artery Hypertension After Degenerative.
Corrado Tamburino, MD, PhD; Davide Capodanno, MD; Angelo Ramondo, MD; Anna Sonia Petronio, MD; Federica Ettori, MD; Gennaro Santoro, MD; Silvio Klugmann,

Corrado Tamburino, MD, PhD; Davide Capodanno, MD; Angelo Ramondo, MD; Anna Sonia Petronio, MD; Federica Ettori, MD; Gennaro Santoro, MD; Silvio Klugmann,
Prosthesis-Patient Mismatch in High Risk Patients with Severe Aortic Stenosis in a Randomized Trial of a Self-Expanding Prosthesis George L. Zorn, III.

Prosthesis-Patient Mismatch in High Risk Patients with Severe Aortic Stenosis in a Randomized Trial of a Self-Expanding Prosthesis George L. Zorn, III.
Techniques in Valve-in-Valve TAVR Vinod H. Thourani, MD Professor of Surgery and Medicine Chief of Cardiothoracic Surgery, Emory Hospital Midtown Co-Director:

Techniques in Valve-in-Valve TAVR Vinod H. Thourani, MD Professor of Surgery and Medicine Chief of Cardiothoracic Surgery, Emory Hospital Midtown Co-Director:
Trancatheter Aortic Valve Implantation (TAVI)

Trancatheter Aortic Valve Implantation (TAVI)
TCT 2015 | San Francisco | October 15, 2015 Transcatheter Aortic Valve Replacement for Failed Surgical Bioprostheses Danny Dvir, MD John G. Webb, MD and.

TCT 2015 | San Francisco | October 15, 2015 Transcatheter Aortic Valve Replacement for Failed Surgical Bioprostheses Danny Dvir, MD John G. Webb, MD and.
TCT 2015 | San Francisco | October 15, 2015 Transcatheter Aortic Valve Replacement for Failed Surgical Bioprostheses Danny Dvir, MD John G. Webb, MD and.

TCT 2015 | San Francisco | October 15, 2015 Transcatheter Aortic Valve Replacement for Failed Surgical Bioprostheses Danny Dvir, MD John G. Webb, MD and.
The Impact of Prior Stroke on the Outcome of Patients with Severe Aortic Stenosis Undergoing Transcatheter Aortic Valve Replacement Romain Didier, MD;

The Impact of Prior Stroke on the Outcome of Patients with Severe Aortic Stenosis Undergoing Transcatheter Aortic Valve Replacement Romain Didier, MD;
Tri-leaflet Aortic Valve. Aortic Stenosis Nishimura, RA et al. 2014 AHA/ACC Valvular Heart Disease Guideline.

Tri-leaflet Aortic Valve. Aortic Stenosis Nishimura, RA et al AHA/ACC Valvular Heart Disease Guideline.
G. Michael Deeb, MD On Behalf of the US Pivotal Trial Investigators 3-Year Results From the US Pivotal High Risk Randomized Trial Comparing Self-Expanding.

G. Michael Deeb, MD On Behalf of the US Pivotal Trial Investigators 3-Year Results From the US Pivotal High Risk Randomized Trial Comparing Self-Expanding.
Ted Feldman MD, FACC, FESC, FSCAI Disclosure Information The following relationships exist: Grant support: Abbott, BSC, Edwards, St Jude, WL Gore Consultant:

Ted Feldman MD, FACC, FESC, FSCAI Disclosure Information The following relationships exist: Grant support: Abbott, BSC, Edwards, St Jude, WL Gore Consultant:
1 Jeffrey J. Popma, MD Professor of Medicine Harvard Medical School Director, Interventional Cardiology Beth Israel Deaconess Medical Center Boston, MA.

1 Jeffrey J. Popma, MD Professor of Medicine Harvard Medical School Director, Interventional Cardiology Beth Israel Deaconess Medical Center Boston, MA.
Longest Follow-up After Implantation of a Self-Expanding Repositionable Transcatheter Aortic Valve: Final Follow-up of the Evolut R CE Study Stephen Brecker,

Longest Follow-up After Implantation of a Self-Expanding Repositionable Transcatheter Aortic Valve: Final Follow-up of the Evolut R CE Study Stephen Brecker,

Similar presentations

Ads by Google